# US 6,730,700 B2 · 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,700 B2
- Document ID: US6730700B2
- Status: Granted
- Kind: B2
- Application number: 10/196,800
- Filed: 2002-07-15
- Published: 2003-04-24
- Granted: 2004-05-04
- Earliest claimed: 1998-12-02
- Assignees: Renovis, Inc.
- Inventors: L. David Waterbury; Allan L. Wilcox; John M. Carney; Farah Mavandadi; Albert Danielzadeh
- Web page: https://patentgrep.com/patent/US6730700B2

## CPC

- C07C 291/02: containing nitrogen-oxide bonds
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R1-R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.

## Claims

### Claim 1

A method for treating a mammal with an inflammation-related condition selected from the group consisting of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and systemic lupus erythematosus which method comprises administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective inflammation-reducing amount of a compound of formula I:
wherein
R1 is selected from the group consisting of:
each R2 is independently selected from a group of the formula:
R3 is selected from the group consisting or hydrogen, alkyl, cycloalkyl and aryl;
R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl; or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl; or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
X is oxygen, sulfur, —S(O)— or —S(O)2—; and
W is oxygen or sulfur; and pharmaceutically-acceptable salts thereof.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the inflammation-related condition is rheumatoid arthritis.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the inflammation-related condition is osteoarthritis.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the inflammation-related condition is ankylosing spondylitis.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the inflammation-related is systemic lupus erythemoatosus.

### Claim 6

A compound of formula I:
wherein
R1 is selected from the group consisting of:
each R2 is independently selected from a group of the formula:
R3 is hydrogen;
R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R6 is selected from the group consisting of alkyl and alkoxycarbonylalkyl;
R7 is hydrogen;
R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl; or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl; or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
X is oxygen, sulfur, —S(O)— or —S(O)2—; and
W is oxygen or sulfur; and pharmaceutically-acceptable salts thereof subject proviso that the compound is not α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.

### Claim 7 (depends on 6)

The compound of claim 6 wherein R6 is selected from the group consisting of ethyl, n-propyl, isopropyl, n-butyl, ethoxycarbonylmethyl and 2-(ethoxycarbonyl)ethyl.

### Claim 8

A compound of formula I:
wherein
R1 is selected from the group consisting of:
each R2 is independently selected from a group of the formula:
R3 is hydrogen;
R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
R8 is selected from the group consisting of alkyl and alkoxyalkyl;
R9 is hydrogen;
R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl; or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl; or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
X is oxygen; and
W is oxygen; and pharmaceutically-acceptable salts thereof subject to the proviso that the compound is not a α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R8 is selected from the group consisting of methyl and methoxyethyl.

### Claim 10

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula I:
wherein
R1 is selected from the group consisting of:
each R2 is independently selected from a group of the formula:
R3 is hydrogen;
R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R6 is selected from the group consisting of alkyl and alkoxycarbonylalkyl;
R7 is hydrogen;
R8 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; or R8 and R9 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
R10 is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl; or R11 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)— or —S(O)2— group;
R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl; or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
X is oxygen, sulfur, —S(O)— or —S(O)13 ; and
W is oxygen or sulfur; and pharmaceutically-acceptable salts thereof to the proviso that the compound is not α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.

### Claim 11 (depends on 10)

The pharmaceutical composition of claim 10 wherein R6 is selected from the group consisting of ethyl, n-propyl, isopropyl, n-butyl, ethoxycarbonylmethyl and 2-(ethoxycarbonyl)ethyl.

### Claim 12

A pharmaceutically composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of formula I:
wherein
R1 is selected from the group consisting of:
each R2 is independently selected from a group of the formula:
R3 is hydrogen;
R4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R5 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl;
R6 and R7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; or R6 and R7 can be joined to form an alkylene or substituted alkylene group having from 2 to 10 carbon atoms;
R8 is selected from the group consisting of alkyl and alkoxyalkyl;
R9 is hydrogen;
R10 is selected from the group consisting at hydrogen, lower alkyl and lower cycloalkyl; or R1 and R10 can be joined to form an alkylene, substituted alkylene, —C(O)——S(O)— or —S(O)2— group;
R11 and R12 are independently selected from the group consisting of lower alkyl and lower cycloalkyl; or R11 and R12 can be joined to form an alkylene group having from 2 to 10 carbon atoms;
X is oxygen; and
W is oxygen; and pharmaceutically-acceptable salts thereof subject to the proviso that the compound is not α-4(acetoxy-3,5-di-tert-butylphenyl-N-tert-butylnitrone.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12 wherein R8 is selected from the group consisting of methyl and methoxyethyl.
